GlaxoSmithKline, Texas A&M To Establish Flu Vaccine Facility In Texas
GlaxoSmithKline plc (GSK) and The Texas A&M University System have announced that the U.S. Department of Health and Human Services (DHHS) has approved the establishment of a $91 million influenza-vaccines manufacturing facility as the anchor of the Center for Innovation in Advanced Development and Manufacturing (CIADM) in Bryan-College Station, TX.
“The Texas A&M Center, anchored by this facility, is expected to bring more than $41 billion in expenditures within the State of Texas over the next 25 years, and will add more than 6,800 direct and related jobs to Texas,” Gov. Rick Perry said.
“GSK is privileged to deepen our commitment to U.S. public health, as part of this unprecedented public-private collaboration to protect against pandemics and bio-threats,” noted Antoon Loomans, Senior Vice President, GSK Vaccines.“In Texas A&M, we have found a partner with a rich tradition of service and with pioneering technologies that will benefit the entire pharmaceutical industry in making vaccines available and accessible to all in need.”
The Texas A&M Center for Innovation is lead by Dr. Brett Giroir, Vice Chancellor for Strategic Initiatives at the Texas A&M System, and a core team of A&M experts in biotechnology, infectious diseases, facilities planning and construction, federal acquisitions/contracting, and government affairs. The partnership with GSK was founded on a long, collaborative relationship between Texas A&M and the Wallonia Region of Belgium, with specific planning for this project beginning in the spring of 2010. Once constructed and operational, the Center’s influenza manufacturing facility will be able to supply 50 million doses of pandemic influenza vaccine within four months of an outbreak.
“GSK’s decision to partner with Texas A&M and bring their vaccine manufacturing to our state is a testament to the investments that the A&M System and the State of Texas have made in the people, infrastructure and technologies, much of which came from critical state programs such as the Emerging Technology Fund,” Giroir said.“GSK brings unequaled influenza vaccine development, manufacturing, and regulatory expertise to our Center.”
The Texas A&M Center for Innovation represents the largest commitment of a global biopharmaceutical company to partner within Texas and will be an important catalyst to the future growth of this industry within the State.